EGF +61 A>G polymorphism does not predict response to first‐generation EGFR tyrosine kinase inhibitors in lung cancer patients-Reference-Cited by-同舟云学术

EGF +61 A>G polymorphism does not predict response to first‐generation EGFR tyrosine kinase inhibitors in lung cancer patients

Published:2020-09-03 Issue:10 Volume:11 Page:2987-2992
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Leal Leticia F.¹²,Laus Ana C.¹,Cavagna Rodrigo¹,Paula Flavia E.³,Oliveira Marco A.⁴,Ribeiro Dayana M.⁵,Hassan Fernanda M.⁵,Miziara José E.⁶,Silva Eduardo C. Albino⁷,Silva Vinicius D.⁷,De Marchi Pedro⁵⁸,Reis Rui M.¹⁹¹⁰^ORCID

Affiliation:

1. Molecular Oncology Research Center Barretos Cancer Hospital Barretos Brazil

2. Barretos School of Health Sciences Dr. Paulo Prata – FACISB Barretos Brazil

3. Molecular Diagnosis Center Barretos Cancer Hospital Barretos Brazil

4. Department of Epidemiology and Biostatistics Barretos Cancer Hospital Barretos Brazil

5. Department of Clinical Oncology Barretos Cancer Hospital Barretos Brazil

6. Department of Surgery Barretos Cancer Hospital Barretos Brazil

7. Department of Pathology Barretos Cancer Hospital Barretos Brazil

8. Oncoclinicas Group Rio de Janeiro Brazil

9. Life and Health Sciences Research Institute (ICVS) School of Medicine, University of Minho Braga Portugal

10. ICVS/3B's – PT Government Associate Laboratory Braga Portugal

Funder